Susan Modesitt
Advanced in Sertoli-Leydig Cell Tumor

Dr. Susan Modesitt

Oncology
Emory Clinic At 1365 Clifton Road
1365 Clifton Road Northeast, BldgA, 
Atlanta, GA 
Offers Telehealth
30 Years of Experience
Advanced in Sertoli-Leydig Cell Tumor
Emory Clinic At 1365 Clifton Road
1365 Clifton Road Northeast, BldgA, 
Atlanta, GA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Susan Modesitt is an Oncologist in Atlanta, Georgia. Dr. Modesitt has been practicing medicine for over 30 years and is rated as an Advanced provider by MediFind in the treatment of Sertoli-Leydig Cell Tumor. Her top areas of expertise are Endometrial Cancer, Ovarian Cancer, Malignant Mixed Mullerian Tumor, Salpingo-Oophorectomy, and Oophorectomy.

Her clinical research consists of co-authoring 87 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
University Of Virginia School Of Medicine, 1995
Residency
University of North Carolina - Chapel Hill
Specialties
Oncology
Licenses
Obstetrics & Gynecology in VA
Board Certifications
American Board Of Obstetrics And Gynecology, 2005
Fellowships
MD Anderson Cancer Center
Hospital Affiliations
Emory University Hospital Midtown
Emory University Hospital
Emory Decatur Hospital
Saint Joseph's Hospital Of Atlanta, Inc
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Piedmont
  • HMO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

Emory Clinic at 1365 Clifton Road
1365 Clifton Road Northeast, BldgA, Atlanta, GA 30322

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Enrollment Status: Active_not_recruiting
Publish Date: October 08, 2025
Intervention Type: Drug, Procedure
Study Drugs: Carboplatin, Letrozole, Paclitaxel
Study Phase: Phase 3
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)
Enrollment Status: Active_not_recruiting
Publish Date: December 10, 2024
Intervention Type: Other, Drug, Biological
Study Drugs: Bevacizumab, Carboplatin, Docetaxel, Gemcitabine Hydrochloride, Paclitaxel
Study Phase: Phase 3
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
Enrollment Status: Completed
Publish Date: November 07, 2022
Intervention Type: Other, Drug, Radiation
Study Drugs: Carboplatin, Cisplatin, Paclitaxel
Study Phase: Phase 3
A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Enrollment Status: Completed
Publish Date: October 20, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
Enrollment Status: Unknown
Publish Date: September 30, 2021
Intervention Type: Other, Drug
Study Drugs: Carboplatin, Metformin hydrochloride, Paclitaxel
Study Phase: Phase 2/Phase 3
Phase II Evaluation of BIBF 1120 in the Treatment of Bevacizumab-Resistant, Persistent, or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Phase II Evaluation of BIBF 1120 in the Treatment of Bevacizumab-Resistant, Persistent, or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Enrollment Status: Completed
Publish Date: October 16, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 5 Less Clinical Trials

87 Total Publications

Silence is not an acceptable response to accusations of corruption: Expertise, integrity, and robust peer review processes safeguard ethical and data driven medical publications.
Silence is not an acceptable response to accusations of corruption: Expertise, integrity, and robust peer review processes safeguard ethical and data driven medical publications.
Journal: Gynecologic oncology reports
Published: July 04, 2025
Similar Doctors
Distinguished in Sertoli-Leydig Cell Tumor
Dr. Gerald A. Feuer
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Distinguished in Sertoli-Leydig Cell Tumor
Dr. Gerald A. Feuer
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Northside Surgical Professional Services LLC

1000 Johnson Fy Rd Ne, Attn Jorge J. Hernandez, 
Atlanta, GA 
 (8.3 miles away)
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Gerald Feuer is a Gynecologic Oncologist and an Oncologist in Atlanta, Georgia. Dr. Feuer is rated as a Distinguished provider by MediFind in the treatment of Sertoli-Leydig Cell Tumor. His top areas of expertise are Endometrial Cancer, Ovarian Carcinosarcoma, Sertoli-Leydig Cell Tumor, Oophorectomy, and Hysterectomy. Dr. Feuer is currently accepting new patients.

Distinguished in Sertoli-Leydig Cell Tumor
Dr. Bunja J. Rungruang
Obstetrics and Gynecology | Oncology
Distinguished in Sertoli-Leydig Cell Tumor
Dr. Bunja J. Rungruang
Obstetrics and Gynecology | Oncology

Wellstar Medical Group LLC

5150 Stilesboro N W Rd, Suite 220, 
Kennesaw, GA 
 (25.9 miles away)
770-424-8222
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Bunja Rungruang is an Obstetrics and Gynecologist and an Oncologist in Kennesaw, Georgia. Dr. Rungruang is rated as a Distinguished provider by MediFind in the treatment of Sertoli-Leydig Cell Tumor. Her top areas of expertise are Ovarian Cancer, Cervical Cancer, Malignant Mixed Mullerian Tumor, Oophorectomy, and Salpingo-Oophorectomy. Dr. Rungruang is currently accepting new patients.

Namita Khanna
Distinguished in Sertoli-Leydig Cell Tumor
Dr. Namita Khanna
Oncology
Distinguished in Sertoli-Leydig Cell Tumor
Dr. Namita Khanna
Oncology

Emory Clinic At 1365 Clifton Road

1365 Clifton Road Northeast, BldgA, 
Atlanta, GA 
 (0.3 miles away)
404-778-3401
Experience:
25+ years
Languages Spoken:
English, Hindi
See accepted insurances
Offers Telehealth

Namita Khanna is an Oncologist in Atlanta, Georgia. Dr. Khanna has been practicing medicine for over 25 years and is rated as a Distinguished provider by MediFind in the treatment of Sertoli-Leydig Cell Tumor. Her top areas of expertise are Ovarian Carcinosarcoma, Cervical Cancer, Sertoli-Leydig Cell Tumor, Ovarian Cancer, and Hysterectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Modesitt's expertise for a condition
ConditionClose
View All 16 Advanced Conditions
View All 25 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile